Key facts
- Neuros Medical’s last known valuation is $164.0M (Jul 2025).
- It has raised $224.1M across 2 recorded rounds; the latest was Later Stage VC ($56.0M) in Jul 2025.
- Notable investors include United States Department of War, Osage University Partners, Argonautic Ventures, Jumpstart Ventures, JobsOhio Ventures — 29 tracked in total.
- Neuros Medical has filed 2 Form Ds with the SEC since 2023, most recently Aug 2025 ($56.0M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Neuros Medical
Funding rounds
2 roundsAbout Neuros Medical
Developer of neuromodulation technology designed to develop proprietary therapies for unmet needs in patients worldwide. The company's technology delivers a high-frequency electrical signal to sensory nerves in the peripheral nervous system to block the pain signal and helps in the treatment of chronic pain in a variety of applications, including post-amputation pain, chronic post-surgical pain, and chronic migraine, enabling patients to get relief from pain at an affordable price.
- Sector
- Healthcare
- HQ
- Aliso Viejo, CA, United States
- Founded
- 2008
- Employees
- 43
- Website
- neurosmedical.com/
- Ownership
- Privately Held (backing)
Neuros Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuros Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuros Medical in its N-PORT filings yet. We sweep new filings monthly.